SJEPD037_R.RNA-Seq
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- age_years
- 1.66
- e1_e2
- E1
- umap1_2d
- -4.322499357
- umap2_2d
- -0.046167641
- umap1_3d
- 0.430502846
- umap2_3d
- 1.397114155
- umap3_3d
- 0.4354695
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.610
- INFLAMMATORY_RESPONSE+0.610
- TNFA_SIGNALING_VIA_NFKB+0.610
- ALLOGRAFT_REJECTION+0.570
- INTERFERON_GAMMA_RESPONSE+0.520
- COMPLEMENT+0.510
- COAGULATION+0.450
- INTERFERON_ALPHA_RESPONSE+0.450
- KRAS_SIGNALING_UP+0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.420
Top 10 suppressed
- G2M_CHECKPOINT-0.440
- E2F_TARGETS-0.430
- MYC_TARGETS_V1-0.420
- DNA_REPAIR-0.380
- MITOTIC_SPINDLE-0.310
- UV_RESPONSE_DN-0.290
- WNT_BETA_CATENIN_SIGNALING-0.290
- OXIDATIVE_PHOSPHORYLATION-0.280
- NOTCH_SIGNALING-0.270
- PROTEIN_SECRETION-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598312 | fetal | fetal | 0.943 |
| 2 | BS_769BDPDB | pilocytic astrocytoma | — | 0.938 |
| 3 | SRR1383018 | GTEX | — | 0.937 |
| 4 | SJEPD001506_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.935 |
| 5 | s_150203_1a | EPN | Posterior Fossa EPN | 0.933 |
| 6 | BS_E4GC9EXR | Ganglioglioma | — | 0.932 |
| 7 | SRR663693 | GTEX | — | 0.930 |
| 8 | SRR1355595 | GTEX | — | 0.930 |
| 9 | SJEPD038_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.921 |
| 10 | ERR2598287 | fetal | fetal | 0.921 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.610 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.610 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.610 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.570 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| COMPLEMENT | 0.510 | Inavolisib | — uncovered |
| COAGULATION | 0.450 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.430 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.420 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.410 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.390 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.390 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.380 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.370 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.370 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.370 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.350 | Inavolisib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.330 | Inavolisib | — uncovered |